Gamma-glutamyl cyclotransferase, a molecule identified from the invasive front of follicular thyroid carcinoma, is useful for differential diagnosis of follicular thyroid tumors
View abstract on PubMed
Summary
This summary is machine-generated.Gamma-glutamyl cyclotransferase (GGCT) shows higher expression in follicular thyroid carcinoma (FTC) than in follicular adenoma (FA). GGCT serves as a promising molecular marker for distinguishing between these thyroid tumors.
Area Of Science
- Endocrinology
- Oncology
- Molecular Biology
Background
- Differentiating follicular thyroid carcinoma (FTC) from follicular adenoma (FA) is crucial for patient management.
- Accurate molecular markers are needed to improve diagnostic accuracy.
Purpose Of The Study
- To identify a reliable molecular marker for distinguishing FTC from FA.
- To evaluate the diagnostic potential of gamma-glutamyl cyclotransferase (GGCT) expression.
Main Methods
- Laser microdissection and cDNA microarray analysis were used to identify candidate markers.
- Immunohistochemical staining for GGCT was performed on formalin-fixed paraffin-embedded (FFPE) tissues from FTC, FA, and follicular tumor of uncertain malignant potential (FT-UMP).
- Ki-67 labeling index was assessed for comparison.
Main Results
- Gamma-glutamyl cyclotransferase (GGCT) was found to be highly expressed in the invasive front of FTC.
- GGCT expression scores were significantly higher in FTC compared to FA (P < 0.0001).
- GGCT achieved 68.8% sensitivity and 87.5% specificity in differentiating FTC from FA (AUC = 0.832), outperforming Ki-67 (50.0% sensitivity, 80.0% specificity, AUC = 0.677).
Conclusions
- Gamma-glutamyl cyclotransferase (GGCT) is a potential molecular marker for differentiating follicular thyroid carcinoma from follicular adenoma.
- Elevated GGCT expression in FTC may correlate with its invasive and proliferative characteristics.

